[EN] BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS PAR HÉTÉROARYLE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2018013774A1
公开(公告)日:2018-01-18
Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
公开了公式(I)至(VIII)的化合物:(I) (II) (III) (IV) (V) (VI) (VII) (VIII);或其立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药,其中R3是与0至3个R3a取代的双环杂芳基团;且R1、R2、R3a、R4和n在此定义。还公开了使用这些化合物作为PAR4抑制剂的方法,以及包含这些化合物的药物组合物。这些化合物用于抑制或预防血小板聚集,用于治疗血栓栓塞障碍或作为血栓栓塞障碍的初级预防。
Reductive Alkylation of 2-Bromoazoles via Photoinduced Electron Transfer: A Versatile Strategy to C<i>sp</i><sup>2</sup>–C<i>sp</i><sup>3</sup> Coupled Products
作者:Amandeep Arora、Kip A. Teegardin、Jimmie D. Weaver
DOI:10.1021/acs.orglett.5b01711
日期:2015.8.7
reductive coupling of arylbromides with unactivated alkenes is introduced as a convenient method that circumvents any need for synthesis of sp3-hybridized coupling partners. The reaction takes place via photoinduced electron transfer from a tertiary amine to an arylbromide that fragments to provide an aryl radical and subsequently reacts with an alkene to form a C–C bond. Conveniently, the amine also
Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R
3a
; and R
1
, R
2
, R
3a
, R
4
, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.